Question from Deputy Albert Dolan - PQ 48540-26

To ask the Minister for Health the reason skyclarys has not been included on the agenda for the recent HSE Drugs Group meeting held in June 2026; when the drug will be considered by the Drugs Group; the timeline for a decision on its prioritisation within the reimbursement process; and the measures being taken to ensure there are no further avoidable delays in progressing access to skyclarys for patients living with Friedreich’s ataxia; and if she will make a statement on the matter.